2[2]Ferrai JG,Wallace JL,Mcknighe W,et al.Induction of cyclooxygenase-1 and 2 in therat stomach during end toxemia:role in resistance to damage.Gastvoenterol,1997,113:195.
3[3]Crofford LJ,Tan B,McCarthy CJ,et al.Involvement of unclear factor kappab in the regulation of cycboxygenase-2 expression by interlenkin-1 in rheumatoid synoriocytes.Arthrits Rhenm,1997,40:2226.
4[5]Cannon G,Caldwell J,Holt P,et al.MK-0966,a specific COX-2 inhibitor,has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial [abstract no.983].Arthritis Rheum,1998,41(Suppl):S196.
5[6]Truitt K,Ettinger W,Schnitzer T,et al.Rofecoxib,a COX-2 specific inhibitor,had Clinical efficacy and overall safety in treating osteoarthritis patients 80 years and older [abstract no.895].In:XIV European League Again Rheumatism Congress,1999,6-11:Glasgow.
6[8]Grover JK,S Vats V.Cyclooxygenase-2 inhbitors:emerging roles in the gut.Int J Colorectal Dis,2003,18:279-291.
7[9]Sorensen HT,Friis S,Norgard B,et al.Risk of cancer in a large cohort of nonaspihn NSAID users:a population-based study.Br J Canaer,2003,88:1687-1692.
8Ehrich EW,Dallob A,Lepeleire ID,et al. Characterization of rofecoxib as a cyclooxygenase - 2 isoform inhibitor and demonstration of analgesia in the dental model[J]. Clin Pharmacol Ther, 1999; 65: 336 - 347.
